- Home
- GNFT vs DOUG Comparison
GNFT vs DOUG Comparison
Compare GNFT & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- DOUG
- Stock Information
- Founded
- GNFT 1999
- DOUG 1911
- Country
- GNFT France
- DOUG United States
- Employees
- GNFT N/A
- DOUG N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- DOUG Building operators
- Sector
- GNFT Health Care
- DOUG Real Estate
- Exchange
- GNFT Nasdaq
- DOUG Nasdaq
- Market Cap
- GNFT 186.3M
- DOUG 161.5M
- IPO Year
- GNFT 2019
- DOUG N/A
- Fundamental
- Price
- GNFT $4.11
- DOUG $2.40
- Analyst Decision
- GNFT Strong Buy
- DOUG
- Analyst Count
- GNFT 1
- DOUG 0
- Target Price
- GNFT $13.00
- DOUG N/A
- AVG Volume (30 Days)
- GNFT 3.9K
- DOUG 690.2K
- Earning Date
- GNFT 09-18-2025
- DOUG 07-31-2025
- Dividend Yield
- GNFT N/A
- DOUG N/A
- EPS Growth
- GNFT N/A
- DOUG N/A
- EPS
- GNFT 0.03
- DOUG N/A
- Revenue
- GNFT $73,187,701.00
- DOUG $1,034,406,000.00
- Revenue This Year
- GNFT $5.15
- DOUG $17.61
- Revenue Next Year
- GNFT N/A
- DOUG N/A
- P/E Ratio
- GNFT $132.29
- DOUG N/A
- Revenue Growth
- GNFT 105.01
- DOUG 8.69
- 52 Week Low
- GNFT $2.55
- DOUG $1.35
- 52 Week High
- GNFT $6.42
- DOUG $3.20
- Technical
- Relative Strength Index (RSI)
- GNFT 58.92
- DOUG 48.88
- Support Level
- GNFT $3.71
- DOUG $2.11
- Resistance Level
- GNFT $4.12
- DOUG $2.59
- Average True Range (ATR)
- GNFT 0.15
- DOUG 0.20
- MACD
- GNFT 0.02
- DOUG -0.01
- Stochastic Oscillator
- GNFT 82.95
- DOUG 41.23
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.